Basic Information

Gene symbol VEGFA Synonyms L-VEGF, MVCD1, VEGF, VPF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description vascular endothelial growth factor A

GTO ID GTC0035
Trial ID NCT00460408
Disease Macular Degeneration
Altered gene VEGFA
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment Macugen|pegaptanib|EYE001
Recruitment statusCompleted
TitleEuropean Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe
Year2006
CountryBelgium|Cyprus|Czech Republic|Denmark|France|Germany|Greece|Ireland|Italy|Poland|Slovakia|Spain|Sweden
Company sponsorPfizer
Other ID(s)A5751019

Clinical Result

Cohort1: Macugen
Administration route intravitreal injection
Pts 403
Age Adult, Older_Adult
Outcome Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection:Increased IOP Measure Type: Number:1.34; Vitreous hemorrhage:0.10; Traumatic cataract; 0.13; Retinal detachment:0.03; Retinal tear:0.03; Endophthalmitis:0|Incidence of POAEs Per Injection Reported by Gender (Females):Increased IOP Measure Type: Number:1.12; Traumatic cataract:0; Endophthalmitis:0
Adverse reactions 21/403(Cardiac disorders; Endocrine disorders; Eye disorders; General disorders; Infections and infestations; Injury, poisoning and procedural complications; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)
Cohort2: Macugen_Avastin
Administration route intravitreal injection
Pts 16
Age Adult, Older_Adult
Outcome Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection:Increased IOP Measure Type: Number:2.19; Vitreous hemorrhage:0.73; Traumatic cataract; 0; Retinal detachment:0; Retinal tear:0; Endophthalmitis:0|Incidence of POAEs Per Injection Reported by Gender (Females):Increased IOP Measure Type: Number:3.19; Traumatic cataract:0; Endophthalmitis:0
Adverse reactions No serious clinical adverse events
Cohort3: Macugen_Lucentis
Administration route intravitreal injection
Pts 75
Age Adult, Older_Adult
Outcome Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection:Increased IOP Measure Type: Number:0.48; Vitreous hemorrhage:0; Traumatic cataract; 0; Retinal detachment:0; Retinal tear:0; Endophthalmitis:0|Incidence of POAEs Per Injection Reported by Gender (Females):Increased IOP Measure Type: Number:0.78; Traumatic cataract:0.17; Endophthalmitis:0
Adverse reactions 2/75(Infections and infestations; Neoplasms benign, malignant and unspecified(incl cysts and polyps))
Cohort4: Macugen_Other AMD Drugs
Administration route intravitreal injection
Pts 7
Age Adult, Older_Adult
Outcome Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection:Increased IOP Measure Type: Number:2.50; Vitreous hemorrhage:0; Traumatic cataract; 0; Retinal detachment:0; Retinal tear:0; Endophthalmitis:0|Incidence of POAEs Per Injection Reported by Gender (Females):Increased IOP Measure Type: Number:3.70; Traumatic cataract:0.17; Endophthalmitis:0
Adverse reactions No serious clinical adverse events

Relationship Graph

Overview of Knowledge Graph